CAS: 135463-81-9; N-(2,3-Dimethyl-5,6,7,8-Tetrahydrofuro[2,3-B]Quinolin-4-yl)-2-(2-Oxopyrrolidin-1-yl)Acetamide

上下游产品

2,3-二甲基-5,6,7,8-四氢呋喃并[2,3-B]喹啉-4-胺 2,3-Dimethyl-5,6,7,8-Tetrahydrofuro[2,3-B]Quinolin-4-Amine 135465-70-2

2,3-二甲基-5,6,7,8-四氢呋喃并[2,3-B]喹啉-4-胺,2-氧代-1-吡咯烷乙酸甲酯置于2-氧代-1-吡咯烷乙酸甲酯体系中,化学反应生成考拉西坦
参考文献:4-Acylaminopyridine Derivative
标题:4-Acylaminopyridine Derivative
摘要:本发明揭示了一种由以下式子(i)表示的新型4-酰胺基吡啶衍生物.##str1##本发明的4-酰胺基吡啶衍生物可用作治疗记忆障碍的药物,如老年性痴呆和阿尔茨海默病,因为它具有直接激活功能失调的胆碱能神经元的作用.

专利信息

专利号:US-2009176740-A1
优先权日:2007-11-30
标题:Treatment of neurological conditions by the co-administration of aniracetam and l-alpha glycerylphosphorylcholine
发明人：PHILLIPS II DAUGLAS JAMES
权利人:PHILLIPS II DAUGLAS JAMES
摘要:Aniracetam (1-[(4-methoxybenzoyl)]-2-pyrrolidinone) is co-administered with the acetylcholine precursor 1-alpha glycerylphosphorylcholine (Alpha GPC, choline alfoscerate, choline alphoscerate) to potentiate cognition enhancing effects in healthy subjects and patients suffering from neurological conditions including Alzheimer's Disease (AD), attention deficit disorder (ADD), Parkinson's Disease, schizophrenia, vascular dementia, post stroke aphasia, anxiety disorders, cerebral atrophy, chronic alcoholism, Down syndrome, dyslexia, and various other neurodegenerative conditions. The co-administration of aniracetam (and other racetam derivatives including oxiracetam) with the acetylcholine precursor 1-alpha glycerylphosphorylcholine decreases negative side-effects such as severe headaches while increasing the synthesis and release of the neurotransmitters acetylcholine and glutamate to facilitate proper brain functioning.